{*}
Add news
March 2010 April 2010 May 2010 June 2010 July 2010
August 2010
September 2010 October 2010 November 2010 December 2010 January 2011 February 2011 March 2011 April 2011 May 2011 June 2011 July 2011 August 2011 September 2011 October 2011 November 2011 December 2011 January 2012 February 2012 March 2012 April 2012 May 2012 June 2012 July 2012 August 2012 September 2012 October 2012 November 2012 December 2012 January 2013 February 2013 March 2013 April 2013 May 2013 June 2013 July 2013 August 2013 September 2013 October 2013 November 2013 December 2013 January 2014 February 2014 March 2014 April 2014 May 2014 June 2014 July 2014 August 2014 September 2014 October 2014 November 2014 December 2014 January 2015 February 2015 March 2015 April 2015 May 2015 June 2015 July 2015 August 2015 September 2015 October 2015 November 2015 December 2015 January 2016 February 2016 March 2016 April 2016 May 2016 June 2016 July 2016 August 2016 September 2016 October 2016 November 2016 December 2016 January 2017 February 2017 March 2017 April 2017 May 2017 June 2017 July 2017 August 2017 September 2017 October 2017 November 2017 December 2017 January 2018 February 2018 March 2018 April 2018 May 2018 June 2018 July 2018 August 2018 September 2018 October 2018 November 2018 December 2018 January 2019 February 2019 March 2019 April 2019 May 2019 June 2019 July 2019 August 2019 September 2019 October 2019 November 2019 December 2019 January 2020 February 2020 March 2020 April 2020 May 2020 June 2020 July 2020 August 2020 September 2020 October 2020 November 2020 December 2020 January 2021 February 2021 March 2021 April 2021 May 2021 June 2021 July 2021 August 2021 September 2021 October 2021 November 2021 December 2021 January 2022 February 2022 March 2022 April 2022 May 2022 June 2022 July 2022 August 2022 September 2022 October 2022 November 2022 December 2022 January 2023 February 2023 March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023 October 2023 November 2023 December 2023 January 2024 February 2024 March 2024 April 2024 May 2024 June 2024 July 2024 August 2024 September 2024 October 2024 November 2024 December 2024 January 2025 February 2025 March 2025 April 2025 May 2025 June 2025 July 2025 August 2025 September 2025 October 2025 November 2025 December 2025 January 2026 February 2026 March 2026 April 2026
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
18
19
20
21
22
23
24
25
26
27
28
29
30
News Every Day |

With GLP‑1 drug ads everywhere, here’s what to know to safely buy them online

If you watched the Super Bowl in 2026, you likely saw Serena Williams share her weight-loss journey on GLP-1 medications in a commercial.

Like millions of others around the country, if you’ve ever considered taking one of these drugs, you probably went online to learn more about where you can get them and how much they cost.

Online searches for GLP-1 medications like Ozempic and Wegovy have risen dramatically since 2022. Advertisements like Williams’s Super Bowl commercial both reflect and help drive that growing demand.

More and more advertisements for weight-loss medications are appearing in people’s daily lives. These ads can be appealing, intrusive, confusing, or even misleading, and have sparked widespread concerns about inappropriate use and adverse events. But the high cost of GLP-1 medications, combined with the lack of adequate coverage by insurance plans, has helped fuel a booming online market for cheaper alternatives.

As health services researchers studying prescription medication safety, we are highly concerned about the risks of online advertisements selling alternative versions of GLP-1 weight-loss medications.

Serena Williams’s Super Bowl ad promoted GLP-1 drugs for weight loss.

Not all GLP-1 medications are the same

As of April 2026, the most popular GLP-1 medications approved by the Food and Drug Administration include semaglutide, sold under the brand names Wegovy, Ozempic, and Rybelsus; tirzepatide, sold as Mounjaro or Zepbound; and orforglipron, sold as Foundayo.

These brand-name medications have undergone rigorous clinical trials and extensive FDA evaluation, including review of clinical data, manufacturing processes, and facility inspections, to ensure safety, quality and effectiveness.

Many of the GLP-1 drugs advertised on the internet are not the FDA-approved medications but rather “compounded” GLP-1 products made in compounding pharmacies. They contain the same active ingredient—semaglutide, tirzepatide or orforglipron—but add minor but clinically important modifications such as using a different salt form, adding different inactive ingredients and varying drug concentrations or dosages. In addition, they may be produced and stored under inconsistent quality standards.

Compounding pharmacies are intended to create personalized versions of FDA-approved medications to meet unique patient needs that cannot be met through the mass-produced brand-name medications. However, there is no evidence to suggest that the modifications being made to GLP-1 medications sold by compounding pharmacies meet those criteria. Instead, companies are using compounding pharmacies to bypass the FDA-approved manufacturers and generate profit.

In February 2026, the FDA released a report alerting patients and providers about the risks of compounded GLP-1 medications.

The report notes the presence of counterfeit Ozempic, the use of non-FDA-approved ingredients such as retatrutide or cagrilintide, and products bypassing regulations by being labeled as “not for human consumption.”

As of July 2024—the most recently issued report—the FDA had received more than 1,000 reports of adverse events related to compounded semaglutide and compounded tirzepatide. These include gastrointestinal effects like nausea, vomiting, and abdominal pain, as well as fainting, headache, migraine, dehydration, acute pancreatitis, and gallstones. These effects occur because drug concentrations in compounded medications can vary significantly, leading to serious dosing errors.

The Better Business Bureau is seeing a rash of “subscription traps” for GLP-1 drugs.

Steps to safely obtain GLP-1 medications online

First, if you or someone you know is considering GLP-1 medications for weight management, it’s important to know that leading medical organizations have specific recommendations for the use of these drugs. For instance, the American Diabetes Association only recommends the use of GLP-1 drugs for weight loss for those with a body mass index, or BMI, of at least 30, or among those with a BMI of 27 or greater if they have at least one other condition such as type 2 diabetes, hypertension, or high cholesterol. People with a BMI below 27 need further clinical evaluation to determine if a GLP-1 medication is appropriate for them.

If you and your doctor determine that it is appropriate to seek GLP-1 medications for weight management, it’s important to avoid compounded versions of GLP-1 drugs unless your healthcare provider specifically recommends them.

But identifying which GLP-1 medications are compounded can be challenging. It’s important to carefully examine how the medication is labeled on the website.

Websites selling compounded versions of GLP-1 drugs are not allowed to use the FDA-approved brand names of products like Ozempic, Wegovy, and Zepbound.

If a product description includes spelling errors or terms such as “compounded,” “generic version,” or “same active ingredient as [brand name],” it often indicates that the product is a compounded formulation. When in doubt, try contacting the online retailer and ask if the product is a compounded drug.

If you decide to obtain GLP-1 medications online, it’s important to choose reliable and transparent sources. The manufacturers of several FDA-approved GLP-1 medications provide official online platforms such as Novocare and LillyDirect.

These allow people to get medication information and transparent pricing and to get the drugs delivered to them at home or to pick them up at a pharmacy. When possible, using these official sources can reduce the risk of encountering misleading advertisements or unverified products.

Red flags

Online retailers that offer GLP-1 drugs without requiring a prescription or medical evaluation are illegal and unsafe. Advertising the ease of getting a prescription or only requiring an online form to obtain a prescription is a red flag. As a rule of thumb, patients should always begin their treatment by consulting with their local primary care provider who can evaluate their complete medical history.

It is also important to verify whether the pharmacy associated with the website is properly licensed and compliant with regulatory standards, since many online sellers rely on compounding pharmacies that are based outside the U.S. or are not appropriately licensed. Therefore, patients should check whether the pharmacy that will ship their medication has a physical address and a telephone number based in the U.S.

Patients should verify whether the pharmacy is registered on the official FDA database of approved compounded pharmacies and licensed as per the board of pharmacy of the state where the pharmacy is physically located.

Using pharmacies that are not registered or licensed is highly unsafe and can result in serious adverse effects. If the online retailer does not clearly disclose which pharmacy they are using, you should contact the retailer to confirm this information.

Finally, even after you receive your medications, you will need to carefully review the product and its label. This can help determine whether the medication being offered corresponds to an FDA-approved product or a compounded formulation. Products that arrive without proper packaging, labeling, or an expiration date, or have a foreign language on the packaging, may be unsafe or unverified products.


Sujith Ramachandran is an associate professor of pharmacy administration at the University of Mississippi.

Liang-Yuan (Claire) Lin is a PhD Candidate in Pharmacy Administration at the University of Mississippi.

This article is republished from The Conversation under a Creative Commons license. Read the original article.


Ria.city






Read also

Harry and Meghan meet survivors of Bondi Beach attack

House punts Trump spy powers extension after conservatives block deal, forcing end-of-month showdown

Vafeades calls for more EU funding for transport in remote regions

News, articles, comments, with a minute-by-minute update, now on Today24.pro

Today24.pro — latest news 24/7. You can add your news instantly now — here




Sports today


Новости тенниса


Спорт в России и мире


All sports news today





Sports in Russia today


Новости России


Russian.city



Губернаторы России









Путин в России и мире







Персональные новости
Russian.city





Friends of Today24

Музыкальные новости

Персональные новости